ProPhase Labs, Inc. Repayments of Long-Term Debt
ProPhase Labs, Inc. (PRPH) reported Repayments of Long-Term Debt of $295.00 thousand for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-08-11.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2020-08-11
- ProPhase Labs, Inc. repayments of long-term debt for fiscal 2016 was $100.00K, a 0.00% change from fiscal 2015.
- ProPhase Labs, Inc. repayments of long-term debt for fiscal 2015 was $100.00K, a 0.00% change from fiscal 2014.
- ProPhase Labs, Inc. repayments of long-term debt for fiscal 2014 was $100.00K, a 0.00% change from fiscal 2013.
- ProPhase Labs, Inc. repayments of long-term debt for fiscal 2013 was $100.00K.
| Period end | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 12 month |
|---|---|---|
| 2020-06-30 | $295.00K 10-Q · filed 2020-08-11 | |
| 2016-12-31 | $100.00K 10-K/A · filed 2018-08-20 | |
| 2015-12-31 | $100.00K 10-K/A · filed 2018-08-20 | |
| 2014-12-31 | $100.00K 10-K · filed 2017-02-24 | |
| 2013-12-31 | $100.00K 10-K · filed 2016-03-29 | |
| 2012-12-31 | $0.00 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |